# QIAGEN completes buyout of NeuMoDx for $248 million

QIAGEN N.V. completed the acquisition of the remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million in cash, gaining full ownership of the diagnostics instruments company.

- Type: Acquisition
- Announced: 2020-09-18
- Where: United States
- Value: $248.0M
- Status: completed
- Products: automated molecular testing platforms, PCR-based diagnostic assays
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Qiagen](https://endata.com/companies/34370.md) (acquirer)
- [NeuMoDx Molecular](https://endata.com/companies/34371.md) (target)

## Sources

- [nasdaq.com](https://www.nasdaq.com/articles/qiagen-qgen-completes-buyout-of-neumodx-expands-portfolio-2020-09-18), 2020-09-18: "The buyout of NeuMoDx completes QIAGEN's portfolio of automated molecular testing solutions based on the polymerase chain reaction technology."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.